Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-β
Open Access
- 31 December 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (1), 84-93
- https://doi.org/10.1158/0008-5472.can-08-2146
Abstract
Transforming growth factor-β (TGF-β) promotes a multitude of diverse biological processes, including growth arrest of epithelial cells and proliferation of fibroblasts. Although the TGF-β signaling pathways that promote inhibition of epithelial cell growth are well characterized, less is known about the mechanisms mediating the positive response to this growth factor. Given that TGF-β has been shown to promote fibrotic diseases and desmoplasia, identifying the fibroblast-specific TGF-β signaling pathways is critical. Here, we investigate the role of mammalian target of rapamycin (mTOR), a known effector of phosphatidylinositol 3-kinase (PI3K) and promoter of cell growth, in the fibroblast response to TGF-β. We show that TGF-β activates mTOR complex 1 (mTORC1) in fibroblasts but not epithelial cells via a PI3K-Akt-TSC2–dependent pathway. Rapamycin, the pharmacologic inhibitor of mTOR, prevents TGF-β–mediated anchorage-independent growth without affecting TGF-β transcriptional responses or extracellular matrix protein induction. In addition to mTORC1, we also examined the role of mTORC2 in TGF-β action. mTORC2 promotes TGF-β–induced morphologic transformation and is required for TGF-β–induced Akt S473 phosphorylation but not mTORC1 activation. Interestingly, both mTOR complexes are necessary for TGF-β–mediated growth in soft agar. These results define distinct and overlapping roles for mTORC1 and mTORC2 in the fibroblast response to TGF-β and suggest that inhibitors of mTOR signaling may be useful in treating fibrotic processes, such as desmoplasia. [Cancer Res 2009;69(1):84–93]Keywords
This publication has 44 references indexed in Scilit:
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Pancreatic cancer–associated stroma productionThe American Journal of Surgery, 2007
- TGF‐β signaling: A tale of two responsesJournal of Cellular Biochemistry, 2007
- Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathwayThe Journal of cell biology, 2007
- Formation and Function of the Myofibroblast during Tissue RepairJournal of Investigative Dermatology, 2007
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- Transforming Growth Factor β Activation of c-Abl Is Independent of Receptor Internalization and Regulated by Phosphatidylinositol 3-Kinase and PAK2 in Mesenchymal CulturesPublished by Elsevier BV ,2006
- Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature, 2004